Patients should be treated by a medical doctor, starting treatments as soon as possible. Do not self-medicate.
The Borody Protocol – 2020-08 – First line treatment for COVID-19
Download from: https://anonymousfiles.io/FLH2fEwH/
INCLUSION OF IVERMECTIN IN THE FIRST THERAPEUTIC LINE OF ACTION FOR COVID-19 A very significant decrease in the Mortality Rate is reported with its use
Dr. Gustavo Aguirre-Chang
Médico egresado de la UNMSM, con Post Grados en Gestión y Salud Ocupacional. Lima, Perú. 2 de Mayo del 2020.
The existing evidence regarding the use of Ivermectin in COVID-19 is reviewed. A report is also made of the cases treated at the local level.
A study recently published in the journal Antiviral Research obtained participants from 169 hospitals around the world, this study includes a high number of patients treated with Ivermectin: 704 and their corresponding 704 controls. The study results indicate that the case fatality rate in patients who used Ivermectin was 6.1 times less compared to patients who did not use Ivermectin (1.4 vs. 8.5%, p <0.0001). In the Dominican Republic, the pulmonologist J. Tavares reports that he is treating 247 patients with Ivermectin with a favorable response in all cases and has not reported any fatal cases. Similarly, at the local level, although to date there are not many documented cases, the case fatality rate has been 0% and it is also observed that in 100% of the cases treated with Ivermectin there is an improvement in the illness and resolution of fever within 48 hours of starting treatment.
A new therapeutic scheme is presented according to the degree of severity and response to treatment, prepared based on the experience of patients treated locally. In the final part, an evaluation of the Risk-Benefit of the use of Ivermectin is made, the conclusion is given that, since there is practically no risk in its use, it is recommended to formalize its inclusion in the first line of therapeutic action for COVID-19. Finally, Recommendations are given mainly related to the supply in Health Establishments throughout the country.
The most powerful treatment to eliminate the coronvirus early, I present my basic protocol: Ivermectin 60mg to 90mg / day for 3 days + Hydroxychloroquine 200mg every 12 hours for 5 days + Azithromycin 250mg / day for 5 days + Zinc 200mg / day for 5 days …
“El tratamiento más potentente para eliminar al coronvirus precozmente, les presento mi protocolo base : Ivermectina 60mg a 90mg / día por 3 días + Hidroxicloroquina 200mg c/12 horas por 5 días + Azitromicina 250mg / día por 5 días + Zinc 200mg / día por 5 días …”
Argentina: Ivermectin accelerate recovery
The protocol being carried out by UBA scientists shows promising results for the treatment and prevention of the disease.
(Translated from spanish) “The preliminary results, from May 27 to June 26, of two protocols using ivermectin carried out by scientists from the University of Buenos Aires (UBA) at the Doctor A. Eurnekian Hospital in Ezeiza were released. The first protocol consists of medication for cases of mild patients (ivermectin and aspirin), moderate (ivermectin, aspirin and dexamethasone) and severe (ivermectin, dexamethasone and enoxaparin).
In the second protocol, intended for healthy hospital personnel, a nasal spray and oral drops are administered to protect the nose and mouth. Hector Carvallo, former assistant professor of Internal Medicine at the UBA, is in charge of both protocols and he carries it out along with other professionals from the UBA, the Hospital Muñiz and Hospital de Ezeiza. Between May 27 and June 26, 161 patients were diagnosed in the protocol.
Mild and / or asymptomatic (138 cases, 85.7% of the total) were treated on an outpatient basis. In some cases, due to housing deficiencies, they were relocated to ad hoc refugee centers. On the 15th day of their respective diagnoses, none required to be admitted to the Hospital.
In all cases, these outpatients received Ivermectin (24 mg orally as a single dose, repeated one week later) and aspirin (250 mg / day, every day). The remaining cases were moderate (10) and severe (13), with bilateral pneumonia, in some cases with comorbidities (COPD, cancer, diabetes, epilepsy, among others).
Each patient received the therapeutic scheme and the dose appropriate to their categorization. As for the evolution of these cases, in 15 it was good and high; in 4 it was good and they are still hospitalized and 3 cases are stable. A single death occurred in an 80-year-old person.”
Peru approves Ivermectin for COVID-19:
Modify the Technical Document: Prevention, Diagnosis and Treatment of people affected by COVID-19 in Peru ministerial resolution N 270-2020-MINSA.